Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
NNX 0.035 +0.0% ABX 51.88 −0.7% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.74 +3.0% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0% NNX 0.035 +0.0% ABX 51.88 −0.7% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.75 +9.4% TUNG 1.74 +3.0% LGO 0.990 −4.8% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.49 +0.9% SGZ 0.045 +0.0% S 0.160 +33.3% GRSL 0.305 −4.7% DEX 0.390 +1.3% WMS 0.040 +0.0%
Financings Neutral

BioNxt Solutions Inc. Announces Extension of Convertible Debentures and Issuance of Warrants

Cash-strapped sublingual drug delivery platform extends debt maturity amid critical liquidity crunch.

By The Northwire Desk — AI Analysis Jun 10, 2026 · 18:31 BNXT · 0.39 BioNxt Solutions Inc.
Executive Summary
  • BioNxt Solutions Inc. amended the terms of six unsecured convertible debentures, extending all maturity dates by one year (from late 2026/early 2027 to late 2027/early 2028).
  • As consideration for the extension, the company will issue 16,900,000 common share purchase warrants to the beneficial holders.
  • The warrants carry a $0.50 exercise price, a 12-month term, and are subject to a 4-month + 1-day statutory hold period.
  • The transaction requires regulatory and corporate approvals, including from the Canadian Securities Exchange.
  • This follows a February 2026 event where $2.7M in convertible debentures were settled via equity issuance.
Material Impact
  • The extension provides immediate operational breathing room, deferring principal repayment obligations and avoiding near-term default.
  • The issuance of 16.9M warrants introduces significant potential dilution (~13% of current shares) at a $0.50 strike, which is above the current trading price.
  • No cash is raised in this transaction; it is a non-cash balance sheet restructuring.
  • The move is a standard liquidity management tactic for a pre-revenue development-stage company but highlights the persistent need for capital.
BNXT · Price
Company Overview
  • BioNxt Solutions Inc. is a drug formulation company focused on sublingual oral thin-film (ODF) delivery systems.
  • Lead program: BNT23001, a sublingual cladribine formulation targeting multiple sclerosis (MS) and myasthenia gravis, designed to improve bioavailability and address dysphagia.
  • Pipeline expansion: Early-stage semaglutide ODF for the GLP-1 market, and evaluation of psychedelic derivative compounds for mental health applications.
  • Strategy: Partner-driven commercialization, leveraging a strong global IP portfolio (European and Eurasian patents) for licensing, co-development, and royalty-based supply agreements.
Read the original news release →

More from BioNxt Solutions Inc.

Jun 23, 2026 · 17:20

Cash-burning sublingual drug delivery platform secures survival capital amid preclinical milestones.

Financings Jun 15, 2026 · 03:45

BioNxt Engages Business Development & Licensing Advisors for Commercialization of Patented Sublingual Cladribine ODF

Other Jun 12, 2026 · 17:15

Cash-Strapped Formulation Platform Raises $2M Lifeline Amid Dilutive Discount and Ongoing Clinical Execution

Financings May 19, 2026 · 03:05

BioNxt Expands GLP-1 Pipeline Amidst MS Platform Progress, Yet Dilution Risks Linger

Other Apr 28, 2026 · 03:05

BioNxt Expands Platform into Psychedelics Amidst Clinical Readiness Milestones

Other Apr 14, 2026 · 03:05

BioNxt Advances MS Drug Manufacturing Amidst Dilution Concerns and Patent Wins

Production / Operations